By Mauro Orru

The European Commission said Friday that it has signed a contract with Sanofi SA and GlaxoSmithKline PLC to secure up to 300 million doses of their potential Covid-19 vaccine.

The commission, the EU's executive arm, didn't disclose financial details but said the contract marks the second deal the EU has struck for the supply of vaccines against coronavirus, following a deal it already signed with British drug maker AstraZeneca PLC.

"Agreements with other companies will be concluded soon and build a diversified portfolio of promising vaccines, based on various types of technologies, increasing our chances to find an effective remedy against the virus," European Commission President Ursula von der Leyen said.

Sanofi and GSK aim to have the vaccine available by the second half of 2021, after starting a Phase 1 and 2 study in September, with a Phase 3 study by the end of 2020.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

September 18, 2020 07:24 ET (11:24 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Sanofi.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Sanofi.